Clinical Trials

Metastatic Hormone-sensitive Prostate Cancer

NCT07226986 2026-04-16

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

123 enrolled

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT06220864 2026-04-14

SNV1521 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

400 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06863272 2026-04-13

IDeate-Prostate02

360 enrolled

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07190300 2026-04-08

TulmiSTAR-02

155 enrolled

Bulbo-Spinal Atrophy, X-Linked

NCT07287150 2026-04-08

InavoPC

Phase 2 Recruiting

100 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT04221542 2026-03-30

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

479 enrolled

Phase 1 Active not recruiting

Bites and Stings, Prostatic Neoplasms

NCT06421935 2026-03-24

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

141 enrolled

Gynecologic

Ovarian Neoplasms

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT06952803 2026-03-10

EvoPAR-PR02

700 enrolled

Prostatic Neoplasms

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

675 enrolled

Neoplasms, Prostatic Neoplasms

NCT07230106 2026-03-03

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

Phase 2 Recruiting

218 enrolled

Prostatic Neoplasms

NCT06855277 2026-02-24

AcTFirst

940 enrolled

Prostatic Neoplasms

NCT07140900 2026-02-13

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Phase 1 Recruiting

60 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Prostatic Neoplasms

NCT05551117 2026-02-09

Tamarack

Phase 2 Terminated

192 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT05701007 2026-01-29

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed

1,083 enrolled 29 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT06764485 2026-01-28

rechARge

960 enrolled

Phase 3 Active not recruiting

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Prostatic Neoplasms

NCT06072196 2025-12-31

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Completed

3,017 enrolled 5 charts

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT04034095 2025-12-15

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Completed

979 enrolled

Prostatic Neoplasms

NCT05914116 2025-11-21

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors